FDA Updates Chantix Cardiovascular Warnings in Light of Clinical Trial Results




WASHINGTON, D.C. — After reviewing the results of a meta-analysis of recent clinical trials, the Food and Drug Administration has ordered Pfizer Inc. (NYSE: PFE) to update the Chantix label to advise consumers to contact their doctor “if they experience new or worsening symptoms of cardiovascular disease.”

According to the Dec. 12 safety communication, a higher occurrence of major adverse cardiovascular events was observed in patients using the smoking cessation drug compared to placebo.

“These events were uncommon in both the Chantix and placebo groups, and the increased risk was not statistically significant, which means it is uncertain whether …






UPCOMING CONFERENCES




HarrisMartin's MDL Conference

December 04, 2024 - New York, NY
Virgin Hotels NYC

MORE DETAILS



HarrisMartin’s Artificial Stone Silicosis Epidemic Litigation Conference

January 10, 2025 - Long Beach, CA
The Westin Long Beach

MORE DETAILS